Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 380 clinical trials
Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE) (CITRINE)

This is a prospective, single center, randomized, open-labled stage III clinical trial comparing the efficacy and safety of anthracyclin followed by weekly paclitaxel versus dose-dense anthracyclin followed by weekly paclitaxel versus dose-dense anthracyclin followed by weekly paclitaxel combined with carboplatin for high-risk, triple-negative early breast cancer.

paclitaxel
HER2
epirubicin
blood transfusion
triple negative breast cancer
  • 20 views
  • 28 Feb, 2022
  • 1 location
A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib Carelizumab Plus Nab-paclitaxel and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

This randomized, open-label phase 3 study will evaluate the safety and efficacy of Carelizumab (an engineered anti-programmed death-ligand 1 [PD-1] antibody) in combination with Nab-paclitaxel and Apatinib, carelizumab plus nab-paclitaxel, and Nab-paclitaxel in Patients with Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer. Participants will be randomized in a …

paclitaxel
measurable disease
HER2
solid tumour
advanced breast cancer
  • 10 views
  • 24 Jan, 2021
  • 1 location
A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

The purpose of this study is to evaluate the efficacy and safety of camrelizumab (an engineered anti-programmed death-ligand 1 [PD-1] antibody) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy in participants with triple negative breast cancer (TNBC). Participants will be randomized in a 1:1 ratio to Arm A (camrelizumab …

triple negative breast cancer
erbb2
HER2
  • 0 views
  • 21 Mar, 2022
  • 1 location
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer (SASCIA)

Phase III, prospective, multi-center, randomized, open label, parallel group, study in patients with HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy with 1:1 allocation to: Arm A: Sacituzumab govitecan (days 1, 8 q3w for eight cycles); Arm B: treatment of physician´s choice (TPC, defined as capecitabine or platinum-based chemotherapy …

invasive carcinoma
capecitabine
mastectomy
BRCA1/2
breast-conserving surgery
  • 8 views
  • 28 Apr, 2022
  • 49 locations
Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment (TORCHLIGHT)

This multicenter, randomized, double-blind study will evaluate the efficacy and safety of Toripalimab (JS001) combined with nab-paclitaxel compared with placebo combined with nab-paclitaxel for first/second line treatment of metastatic or recurrent triple-negative breast cancer (TNBC).

epidermal growth factor
measurable disease
triple negative breast cancer
triple-negative breast cancer
progesterone receptor
  • 48 views
  • 10 May, 2022
  • 68 locations
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (BEGONIA)

This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer

paclitaxel
trastuzumab
HER2
triple negative breast cancer
erbb2
  • 445 views
  • 23 May, 2022
  • 32 locations
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC (CAPItello-290)

Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)

formalin-fixed paraffin-embedded
paclitaxel
mammogram
measurable disease
breast cancer
  • 1671 views
  • 24 May, 2022
  • 32 locations
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMpassion030)

This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator's choice), and cyclophosphamide, compared with paclitaxel followed by dose-dense doxorubicin or epirubicin (investigator's choice) and cyclophosphamide alone in patients with Stage II-III TNBC (Triple Negative Breast …

doxorubicin
mastectomy
cyclophosphamide
breast-conserving surgery
triple-negative breast cancer
  • 394 views
  • 04 Jun, 2022
  • 415 locations
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, and Children in India and Healthy Adolescents and Children in the Republic of South Africa (MET55)

The primary objective of this study is to demonstrate the non-inferiority of immunogenicity of a single dose of MenACYW conjugate vaccine compared to Menactra® in adolescents and children aged 2 to 17 years in terms of serum bactericidal assay using human complement (hSBA) titers. The secondary objectives of the study …

Accepts healthy volunteers
  • 310 views
  • 30 May, 2022
  • 12 locations
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss (EPIK-B3)

The purpose of this study is to determine whether treatment with alpelisib in combination with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who carry either a PIK3CA mutation (Study Part A) or have PTEN loss (Study Part B1) or PTEN loss without PIK3CA …

paclitaxel
measurable disease
PIK3CA
metastasis
PTEN
  • 73 views
  • 02 Jun, 2022
  • 183 locations